TVTX
Travere Therapeutics Inc
NASDAQ: TVTX · HEALTHCARE · BIOTECHNOLOGY
$40.10
-1.93% today
Updated 2026-04-29
Market cap
$3.70B
P/E ratio
—
P/S ratio
7.55x
EPS (TTM)
$-0.57
Dividend yield
—
52W range
$14 – $43
Volume
1.9M
Travere Therapeutics Inc (TVTX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-5.21%
Operating margin
-25.00%
ROE
-57.80%
ROA
-6.55%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2010 | — | $-18266.00 | — | — | — |
| 2011 | — | $-14825.00 | — | — | — |
| 2012 | — | $-30.34M | — | — | — |
| 2013 | — | $-33.82M | — | — | — |
| 2014 | $28.20M | $-110.94M | 97.98% | -282.97% | -393.35% |
| 2015 | $99.89M | $117.24M | 97.81% | -50.80% | 117.36% |
| 2016 | $133.59M | $-47.90M | 96.59% | -43.58% | -35.86% |
| 2017 | $154.94M | $-59.73M | 97.67% | -34.72% | -38.55% |
| 2018 | $164.25M | $-102.68M | 96.63% | -48.73% | -62.51% |
| 2019 | $175.34M | $-146.43M | 97.01% | -56.92% | -83.51% |
| 2020 | $198.32M | $-169.43M | 96.91% | -88.83% | -85.43% |
| 2021 | $131.84M | $-180.09M | 97.10% | -151.27% | -136.60% |
| 2022 | $109.46M | $-278.48M | 95.96% | -292.17% | -254.41% |
| 2023 | $145.24M | $-111.40M | 92.12% | -267.24% | -76.70% |
| 2024 | $233.18M | $-321.55M | 96.68% | -138.88% | -137.90% |
| 2025 | $490.73M | $-50.26M | 85.51% | -12.80% | -10.24% |